ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Sun Pharmaceutical Industries Ltd.

Company Background

Sun Pharmaceutical is India's largest drugmaker. It sells mainly generic drugs, an area in which Indian companies do well, in more than 150 countries, including the U.S. It has over 20 production bases around the world and supplies more than 1,000 products. It has succeeded in expanding its business globally, given that domestic sales account for only about 30% of its group sales. It has built a solid business base especially in the U.S., generating more around 50% of sales in that market.

 

The company was founded in 1983 by Dilip Shanghvi, who serves as managing director. It brought online its first active pharmaceutical ingredients factory in the western Indian state of Gujarat in 1995. It has been on a growth path recently on the back of the global expansion of India's generic drug business. Shanghvi is known for his aggressive merger and acquisition strategy and has expanded his company through buyouts including overseas companies. In 2014, it bought Ranbaxy Laboratories, an Indian drugmaker, which cemented its place at the top of India's pharmaceutical industry.

 

Shanghvi and other founding family members and affiliate companies own more than 60% of shares in Sun Pharmaceutical. Shanghvi is one of India's richest men, and he and his family are actively investing in India.

Business Summary

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It operates through the following geographical segments: India, United States of America, Emerging Markets, and Rest of the World. It offers tablets, capsules, injectable, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1982 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2020 INRUSD
Revenue328,375M4,631.13M
Gross Profit151,919.20M2,142.54M
Operating income49,213.70M694.06M
Income before tax50,095.90M706.51M
Net income37,649.30M530.97M
EBITDA69,741.50M983.57M
Diluted EPS15.690.22
Dividends Per Share----
Total Assets682,524.60M9,021.98M
Total liabilities191,277.70M2,528.41M
Total equity452,644.50M5,983.30M
Operating cash flow66,775.20M941.74M
Currency in INRCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 281,086.10M 313,081.40M 264,155.40M 290,659.10M 328,375M
Gross Profit 149,951.40M 158,651.20M 109,049.50M 122,523.20M 151,919.20M
Operating income 75,140.60M 84,884.50M 41,097.80M 49,220M 49,213.70M
Income before tax 65,706.30M 90,478.70M 34,789.80M 38,102M 50,095.90M
Net income 45,457.10M 69,643.70M 20,957M 26,654.20M 37,649.30M
EBITDA 85,515.90M 97,532M 56,096.20M 66,752.50M 69,741.50M
Diluted EPS 18.90 29 8.73 11.10 15.69
Dividends Per Share 1 3.50 2 2.75 --
Total Assets 559,415.90M 619,117.90M 652,045.20M 655,799.50M 682,524.60M
Total liabilities 188,572.10M 214,674.70M 230,062.50M 208,573.50M 191,277.70M
Total equity 329,824.80M 366,396.70M 383,141.10M 414,090.60M 452,644.50M
Operating cash flow 67,726.30M 71,269.50M 39,781.60M 24,425.10M 66,775.20M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 4,293.30M 4,668.88M 4,097.58M 4,155.67M 4,631.13M
Gross Profit 2,290.35M 2,365.91M 1,691.58M 1,751.76M 2,142.54M
Operating income 1,147.69M 1,265.85M 637.51M 703.71M 694.06M
Income before tax 1,003.59M 1,349.27M 539.66M 544.76M 706.51M
Net income 694.31M 1,038.57M 325.08M 381.08M 530.97M
EBITDA 1,306.16M 1,454.46M 870.16M 954.38M 983.57M
Diluted EPS 0.28 0.43 0.13 0.15 0.22
Dividends Per Share 0.01 0.05 0.03 0.03 --
Total Assets 8,447.51M 9,534.42M 9,997.36M 9,466.61M 9,021.98M
Total liabilities 2,847.55M 3,305.99M 3,527.39M 3,010.80M 2,528.41M
Total equity 4,980.55M 5,642.51M 5,874.44M 5,977.48M 5,983.30M
Operating cash flow 1,034.44M 1,062.81M 617.09M 349.21M 941.74M

Valuation Measures

Mar 2020
PER22.44
ROA5.62%
ROE8.68%
Operating margin14.98%
Profit margin11.46%

Key executives

  • Managing Director & Executive Director: Dilip Shantilal Shanghvi
  • Chief Financial Officer: C. S. Muralidharan
  • SVP & Chief Information Officer: Atanu Roy
  • Compliance Officer & Senior GM-Secretarial: Ashok I. Bhuta
  • SVP & Head-Human Resources: Sapna Purohit

Shareholders

  • Shanghvi Finance Pvt Ltd. (41.9%)
  • SHANGHVI DILIP SHANTILAL (9.5%)
  • Life Insurance Corp of India (6.3%)
  • ICICI Prudential Asset Management Co. Ltd. (3.4%)
  • SBI Funds Management Pvt Ltd. (1.6%)
  • The Vanguard Group, Inc. (1.6%)
  • VALIA RAKSHA SUDHIR (1.4%)
  • Nippon Life India Asset Management Ltd. (Invt Mgmt) (1.4%)
  • Lakshdeep Investments & Finance Pvt Ltd. (1.3%)
  • UTI Asset Management Co. Ltd. (Investment Management) (0.9%)

Contact Details

  • Website:http://www.sunpharma.com
  • Address: CTS No. 201 B/1, Sun House, Western Express Highway, Mumbai, 400063, India
  • Phone: +91.22.43244324

Related Companies

  • Sun Pharma Canada, Inc.
  • Sun Pharma Global, Inc.
  • Sun Pharma de Venezuela CA
  • Faststone Mercantile Company Pvt Ltd.
  • Green Eco Development Centre Ltd.
  • Ranbaxy Nigeria Ltd.
  • Sun Pharmaceuticals Germany GmbH
  • Sun Pharmaceuticals Morocco LLC Sarlau
  • Sun Pharma (Netherlands) BV
  • Sun Pharmaceutical Industries (Australia) Pty Ltd.
  • Ocular Technologies SARL
  • Sun Pharmaceutical Industries Ltd. /7 Brands/
  • Sun Pharmaceutical Industries Ltd. /Bryan Ops/
  • Sun Pharma Japan Ltd.
  • GlaxoSmithKline Plc /Opiates Business/
  • Sun Pharma Laboratories Ltd.
  • Sun Global Canada Pty Ltd.
  • Sun Pharmaceutical Industries Europe BV
  • Aditya Acquisition Co. Ltd.
  • SPIL de Mexico SA de CV
  • Sun Pharma de Mexico SA de CV
  • Tamil Nadu Dadha Pharmaceuticals Ltd.
  • Pradeep Drug Co. Ltd.
  • Pola Pharma, Inc.
  • Ranbaxy
  • Pharmalucence, Inc.
  • Alkaloida Chemical Co. Exclusive Group Ltd.
  • Sun Pharmaceutical Industries Key Employees Benefit Trust
  • Sun Pharmaceutical Industries, Inc.
  • Chattem Chemicals, Inc.

Competitors

  • Lupin Limited
  • Cipla Limited
  • Alkem Laboratories Ltd.
  • Torrent Pharmaceuticals Ltd
  • Cadila Healthcare Limited
  • GlaxoSmithKline Pharmaceuticals Limited
  • Abbott India Limited
  • Novo Nordisk A/S Class B
  • Dr. Reddy's Laboratories Ltd.
  • Antibiotice SA
  • ANI Pharmaceuticals, Inc.
  • Amneal Pharmaceuticals, Inc. Class A
  • Zentiva SA
  • Piramal Enterprises Ltd.
  • Biofrontera AG
  • Antares Pharma, Inc.
  • Aerie Pharmaceuticals, Inc.
  • Nicox SA
  • Curis, Inc.
  • Intec Pharma Ltd
  • Plus Therapeutics, Inc.
  • Acura Pharmaceuticals, Inc.
  • Evolus, Inc.
  • Sol-Gel Technologies Ltd.
Last Updated on 3 Jul, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media